The identified patterns of distribution of tumor-associated MCs depending on the content of Melan-A+ cells confirm the participation of melanin in modulating the activity of innate immunity and indicate its possible role as a pharmacological target aimed at restoring the antitumorogenic potentials of MCs. The gene discussed is MLANA; the disease is neoplasm.